National Comprehensive Cancer Network



About NCCN

New Treatment Options Featured in NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines

JENKINTOWN, PA — The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, announces that the NCCN Non-Small Cell Lung Cancer Guideline has recently been updated to broaden the options for treatment of advanced disease. NCCN’s panel of oncology experts added pemetrexed (Alimta®, Eli Lilly and Company) as an option for second-line therapy for lung cancer. The panel indicated that it has been shown to be equivalent to docetaxel (Taxotere®, Sanofi-Aventis) in efficacy but with less toxicity. The expert panel also added a recommendation for single agent erlotinib (Tarceva™, Genentech) for patients with advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Concurrent chemoradiation therapy was added as a primary treatment option for patients with unresectable stage IIIB disease who do not have effusions. Carboplatin (Paraplatin®, Bristol-Myers Squibb Oncology) in combination with paclitaxel (Taxol®, Bristol-Myers Squibb Oncology) was also added as an alternate regimen to existing recommendations for the cisplatin (Platinol®, Bristol-Myers Squibb Oncology) based combination as adjuvant chemotherapy.

“NCCN Clinical Practice Guidelines in Oncology™ are widely recognized as the standard for clinical policy in the oncology community. Additionally, they are being used increasingly by insurance and managed care companies to help establish coverage policy,” said William T. McGivney, Ph.D., CEO of the NCCN. “As such, NCCN recognizes its responsibility to provide up-to-date information to inform decision-making. Thus, the NCCN Guidelines process is an ongoing, continual process.”

NCCN Clinical Practice Guidelines in Oncology™ are available free of charge on CD-ROM. These can be ordered from NCCN by calling 215-690-0300. The most up-to-date versions of the guidelines can be found at www.nccn.org.

The National Comprehensive Cancer Network (NCCN), an alliance of 19 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to cancer patients. Through the leadership and expertise of clinical professionals at NCCN member institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. NCCN programs include: Clinical Practice Guidelines in Oncology™, Drugs & Biologics Compendium™, Treatment Guidelines for Patients, the Journal of the National Comprehensive Cancer Network (JNCCN), Leukemia Resource Line, educational conferences and symposia for clinicians, Oncology Outcomes Project, Clinical Trials Network, Cancer Case Manager™, and collaborations with managed care organizations.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.

The NCCN Member Institutions are:

  • Fred & Pamela Buffett Cancer Center
  • Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
  • City of Hope Comprehensive Cancer Center
  • Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
  • Duke Cancer Institute
  • Fox Chase Cancer Center
  • Huntsman Cancer Institute at the University of Utah
  • Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • Mayo Clinic Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Moffitt Cancer Center
  • The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
  • Roswell Park Cancer Institute
  • Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
  • St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
  • Stanford Cancer Institute
  • University of Alabama at Birmingham Comprehensive Cancer Center
  • UC San Diego Moores Cancer Center
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • University of Colorado Cancer Center
  • University of Michigan Comprehensive Cancer Center
  • The University of Texas MD Anderson Cancer Center
  • University of Wisconsin Carbone Cancer Center
  • Vanderbilt-Ingram Cancer Center
  • Yale Cancer Center/Smilow Cancer Hospital